UNSPSC 51292018: Tranylcypromine

This classification denotes a monoamine oxidase inhibitor with the molecular formula C9H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E3V44J4Z9, chemically known as cyclopropylamine, trans-2-phenyl- but generally known as tranylcypromine, which bears US NIH Compound Identifier 5530. European Medicines Agency schedules Tranylcypromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11218MIG.

UNSPSC 51292018 Tranylcypromine is a Commodity code, but the recent state and local opportunities posted under it do not align with tranylcypromine procurement — the recorded solicitations target naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription program capabilities rather than this specific monoamine oxidase inhibitor antidepressant. The code shows little relevant recent activity in state and local procurement, with a substantial mismatch between the code's nominal scope and the work actually being solicited. The few opportunities tagged to this code reflect broader pharmaceutical supply and distribution contracting, where state health departments, county health systems, and cooperative purchasing alliances seek inventory of multiple drug classes, compliance with manufacturing and supply-chain security standards, and vendor participation in established wholesaler networks.

Recent opportunities appear in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across state and local government facilities, with proposals due March 26, 2026, and awarded vendors effective July 1, 2026. Vendors responding to the MMCAP RFP must maintain relationships with at least two of three authorized wholesalers, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee. The code does not see sufficient tranylcypromine-specific procurement volume to support a focused pursuit strategy at this time.